The National Montelukast Survey

Michael David Thomas, N. Barnes, David Brendan Price, H. Tate

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Background: Randomized controlled trials have demonstrated the efficacy of montelukast for treating asthma; whether this can be extrapolated to clinical effectiveness in routine practice has yet to be established. Objective: To examine the use, effectiveness, and tolerability of montelukast in clinical practice for treating asthma and to explore prognostic factors that could predict a favorable response to the drug.

Methods: This was a retrospective, cross-sectional, observational study of clinical outcomes seen in patients prescribed montelukast for asthma that used routinely collected clinical information. Data were collected on all consenting patients who had been prescribed montelukast for asthma irrespective of the continuation or duration of treatment. Independent observers, treating physicians, and patients assessed certain outcomes after the initiation of montelukast, including the general asthma response and changes in activity-related symptoms.

Results: Fifty-six centers in the United Kingdom (20 primary care and 36 secondary care) participated. The analysis was based on 1351 eligible patients for whom essential data were available. Eight hundred thirty patients (66.4%; 95% CI, 63.8% to 69.0%) were recorded as having shown an improvement in their asthma control, and 103 (8.2%; 95% CI, 6.8% to 9.9%) experienced a dramatic improvement. The greatest proportion of patients responding was seen in those with mild to moderate asthma. Montelukast was well tolerated; no new adverse events were recorded.

Conclusions: Montelukast is an effective, well-tolerated treatment for asthma in routine practice. The overall response rate and tolerability seen in this survey are similar to those reported in randomized clinical trials.

Original languageEnglish
Pages (from-to)47-54
Number of pages7
JournalJournal of Allergy and Clinical Immunology
Volume115
Issue number1
Early online date31 Dec 2004
DOIs
Publication statusPublished - 1 Jan 2005

Keywords

  • montelukast
  • survey
  • retrospective
  • inhaled beclomethasone
  • oral montelukast
  • controlled-trial
  • asthma
  • therapy
  • children
  • antagonists
  • budesonide
  • adults

Cite this

The National Montelukast Survey. / Thomas, Michael David; Barnes, N.; Price, David Brendan; Tate, H.

In: Journal of Allergy and Clinical Immunology, Vol. 115, No. 1, 01.01.2005, p. 47-54.

Research output: Contribution to journalArticle

Thomas, Michael David ; Barnes, N. ; Price, David Brendan ; Tate, H. / The National Montelukast Survey. In: Journal of Allergy and Clinical Immunology. 2005 ; Vol. 115, No. 1. pp. 47-54.
@article{a61f2afa778c484ca36a463d5d1562f1,
title = "The National Montelukast Survey",
abstract = "Background: Randomized controlled trials have demonstrated the efficacy of montelukast for treating asthma; whether this can be extrapolated to clinical effectiveness in routine practice has yet to be established. Objective: To examine the use, effectiveness, and tolerability of montelukast in clinical practice for treating asthma and to explore prognostic factors that could predict a favorable response to the drug.Methods: This was a retrospective, cross-sectional, observational study of clinical outcomes seen in patients prescribed montelukast for asthma that used routinely collected clinical information. Data were collected on all consenting patients who had been prescribed montelukast for asthma irrespective of the continuation or duration of treatment. Independent observers, treating physicians, and patients assessed certain outcomes after the initiation of montelukast, including the general asthma response and changes in activity-related symptoms.Results: Fifty-six centers in the United Kingdom (20 primary care and 36 secondary care) participated. The analysis was based on 1351 eligible patients for whom essential data were available. Eight hundred thirty patients (66.4{\%}; 95{\%} CI, 63.8{\%} to 69.0{\%}) were recorded as having shown an improvement in their asthma control, and 103 (8.2{\%}; 95{\%} CI, 6.8{\%} to 9.9{\%}) experienced a dramatic improvement. The greatest proportion of patients responding was seen in those with mild to moderate asthma. Montelukast was well tolerated; no new adverse events were recorded.Conclusions: Montelukast is an effective, well-tolerated treatment for asthma in routine practice. The overall response rate and tolerability seen in this survey are similar to those reported in randomized clinical trials.",
keywords = "montelukast, survey, retrospective, inhaled beclomethasone, oral montelukast, controlled-trial, asthma, therapy, children, antagonists, budesonide, adults",
author = "Thomas, {Michael David} and N. Barnes and Price, {David Brendan} and H. Tate",
year = "2005",
month = "1",
day = "1",
doi = "10.1016/j.jaci.2004.10.011",
language = "English",
volume = "115",
pages = "47--54",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby/Elsevier,",
number = "1",

}

TY - JOUR

T1 - The National Montelukast Survey

AU - Thomas, Michael David

AU - Barnes, N.

AU - Price, David Brendan

AU - Tate, H.

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Background: Randomized controlled trials have demonstrated the efficacy of montelukast for treating asthma; whether this can be extrapolated to clinical effectiveness in routine practice has yet to be established. Objective: To examine the use, effectiveness, and tolerability of montelukast in clinical practice for treating asthma and to explore prognostic factors that could predict a favorable response to the drug.Methods: This was a retrospective, cross-sectional, observational study of clinical outcomes seen in patients prescribed montelukast for asthma that used routinely collected clinical information. Data were collected on all consenting patients who had been prescribed montelukast for asthma irrespective of the continuation or duration of treatment. Independent observers, treating physicians, and patients assessed certain outcomes after the initiation of montelukast, including the general asthma response and changes in activity-related symptoms.Results: Fifty-six centers in the United Kingdom (20 primary care and 36 secondary care) participated. The analysis was based on 1351 eligible patients for whom essential data were available. Eight hundred thirty patients (66.4%; 95% CI, 63.8% to 69.0%) were recorded as having shown an improvement in their asthma control, and 103 (8.2%; 95% CI, 6.8% to 9.9%) experienced a dramatic improvement. The greatest proportion of patients responding was seen in those with mild to moderate asthma. Montelukast was well tolerated; no new adverse events were recorded.Conclusions: Montelukast is an effective, well-tolerated treatment for asthma in routine practice. The overall response rate and tolerability seen in this survey are similar to those reported in randomized clinical trials.

AB - Background: Randomized controlled trials have demonstrated the efficacy of montelukast for treating asthma; whether this can be extrapolated to clinical effectiveness in routine practice has yet to be established. Objective: To examine the use, effectiveness, and tolerability of montelukast in clinical practice for treating asthma and to explore prognostic factors that could predict a favorable response to the drug.Methods: This was a retrospective, cross-sectional, observational study of clinical outcomes seen in patients prescribed montelukast for asthma that used routinely collected clinical information. Data were collected on all consenting patients who had been prescribed montelukast for asthma irrespective of the continuation or duration of treatment. Independent observers, treating physicians, and patients assessed certain outcomes after the initiation of montelukast, including the general asthma response and changes in activity-related symptoms.Results: Fifty-six centers in the United Kingdom (20 primary care and 36 secondary care) participated. The analysis was based on 1351 eligible patients for whom essential data were available. Eight hundred thirty patients (66.4%; 95% CI, 63.8% to 69.0%) were recorded as having shown an improvement in their asthma control, and 103 (8.2%; 95% CI, 6.8% to 9.9%) experienced a dramatic improvement. The greatest proportion of patients responding was seen in those with mild to moderate asthma. Montelukast was well tolerated; no new adverse events were recorded.Conclusions: Montelukast is an effective, well-tolerated treatment for asthma in routine practice. The overall response rate and tolerability seen in this survey are similar to those reported in randomized clinical trials.

KW - montelukast

KW - survey

KW - retrospective

KW - inhaled beclomethasone

KW - oral montelukast

KW - controlled-trial

KW - asthma

KW - therapy

KW - children

KW - antagonists

KW - budesonide

KW - adults

U2 - 10.1016/j.jaci.2004.10.011

DO - 10.1016/j.jaci.2004.10.011

M3 - Article

VL - 115

SP - 47

EP - 54

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 1

ER -